Vattemi Emanuela, Graiff Claudio, Sava Teodoro, Pedersini Rebecca, Caldara Alessia, Mandarà Marta
Central Regional Hospital, Division of Medical Oncology, Bolzano, Italy.
Expert Rev Anticancer Ther. 2008 Mar;8(3):393-402. doi: 10.1586/14737140.8.3.393.
Salivary gland carcinomas are rare cancers, comprising 1-5% of head and neck cancers. They represent a morphologically and clinically diverse group of tumors. The most commonly histopathologic types are mucoepidermoid cancer, adenoid cystic cancer and adenocarcinomas. Malignant salivary gland tumors generally present as painless, slow-growing tumors that are indistinguishable from benign tumors. Surgery is the principal treatment and is curative in early stage. Radiation therapy should be considered in most patients after surgical resection. Chemotherapy is reserved for palliative treatment of metastatic disease but results are disappointing. Recent studies have investigated the role of targeted therapies in a palliative setting. Multicentre cooperative group clinical trials are required to assess novel therapies to maximize patient resources in this uncommon tumor.
涎腺癌是罕见的癌症，占头颈癌的1%-5%。它们是一组形态学和临床特征各异的肿瘤。最常见的组织病理学类型是黏液表皮样癌、腺样囊性癌和腺癌。恶性涎腺肿瘤通常表现为无痛、生长缓慢的肿瘤，与良性肿瘤难以区分。手术是主要治疗方法，早期可治愈。大多数患者术后应考虑放疗。化疗仅用于转移性疾病的姑息治疗，但效果令人失望。最近的研究探讨了靶向治疗在姑息治疗中的作用。需要多中心合作组临床试验来评估新疗法，以在这种罕见肿瘤中最大限度地利用患者资源。
